Sequoia Pharmaceuticals (Gaithersburg, MD) drug developer focused on the treatment of drug-resistant HIV infections, has raised $35M in Series C funding. The deal was led by Wellcome Trust and existing investors Healthcare Ventures, Sofinnova Partners and Aberdare Ventures. The round was also joined by MedImmune Ventures.
Leave a Comment » | 
I - Series C, R - MID-ATLANTIC, X - HIV | 
Permalink
Posted by arubenstein
VIRxSYS Corporation (Gaithersburg, MD), who is developing genetic therapies for HIV and cancer, closed a $20M Series G round of financing, the company has raised a total of $87M to date. The financing will be used to support research and clinical programs including VRX496, a gene-based immunotherapy for the treatment of HIV. Phase II clinical trials of VRX496 are underway. Financial backers were not announced.
Leave a Comment » | 
I - Series G, R - MID-ATLANTIC, X - HIV | 
Permalink
Posted by arubenstein
You are currently browsing the archives for the X - HIV category.
